These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
198 related items for PubMed ID: 7628045
21. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR. Cancer Res; 1993 Jun 01; 53(11):2581-6. PubMed ID: 8388318 [Abstract] [Full Text] [Related]
22. The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents. Hrubisko M, McGown AT, Fox BW. Biochem Pharmacol; 1993 Jan 07; 45(1):253-6. PubMed ID: 8424817 [Abstract] [Full Text] [Related]
23. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents. Hamberger J, Liebeke M, Kaiser M, Bracht K, Olszewski U, Zeillinger R, Hamilton G, Braun D, Bednarski PJ. Anticancer Drugs; 2009 Aug 07; 20(7):559-72. PubMed ID: 19491657 [Abstract] [Full Text] [Related]
24. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, Harrap KR. Br J Cancer; 1989 Apr 07; 59(4):527-34. PubMed ID: 2653399 [Abstract] [Full Text] [Related]
25. Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine. Fishel ML, Gamcsik MP, Delaney SM, Zuhowski EG, Maher VM, Karrison T, Moschel RC, Egorin MJ, Dolan ME. Cancer Chemother Pharmacol; 2005 Apr 07; 55(4):333-342. PubMed ID: 15723259 [Abstract] [Full Text] [Related]
26. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours. Goddard PM, Orr RM, Valenti MR, Barnard CF, Murrer BA, Kelland LR, Harrap KR. Anticancer Res; 1996 Apr 07; 16(1):33-8. PubMed ID: 8615631 [Abstract] [Full Text] [Related]
27. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. Jones M, Siracky J, Kelland LR, Harrap KR. Br J Cancer; 1993 Jan 07; 67(1):24-9. PubMed ID: 8427780 [Abstract] [Full Text] [Related]
28. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice. Kido Y, Khokhar AR, Yoshida M, Thai GW, Siddik ZH. Drug Metab Dispos; 1994 Jan 07; 22(2):312-7. PubMed ID: 8013287 [Abstract] [Full Text] [Related]
29. Differential properties of cisplatin and tetraplatin with respect to cytotoxicity and perturbation of cellular glutathione levels. Müller MR, Wright KA, Twentyman PR. Cancer Chemother Pharmacol; 1991 Jan 07; 28(4):273-6. PubMed ID: 1879044 [Abstract] [Full Text] [Related]
30. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines. Mistry P, Kelland LR, Loh SY, Abel G, Murrer BA, Harrap KR. Cancer Res; 1992 Nov 15; 52(22):6188-93. PubMed ID: 1423261 [Abstract] [Full Text] [Related]
31. Induction of gamma-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line. el-akawi Z, Zdanowicz J, Creaven PJ, Abu-hadid M, Perez R, Pendyala L. Oncol Res; 1996 Nov 15; 8(10-11):415-23. PubMed ID: 9114434 [Abstract] [Full Text] [Related]
33. Synthesis, cytotoxicity, and apoptosis induction study of antitumor dinuclear platinum(II) complexes. Xu G, Gou S, Gao C. Arch Pharm (Weinheim); 2013 Apr 15; 346(4):308-13. PubMed ID: 23447402 [Abstract] [Full Text] [Related]
34. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, Ozols RF. Cancer Res; 1987 Jan 15; 47(2):414-8. PubMed ID: 3539322 [Abstract] [Full Text] [Related]
35. Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)]. Mellish KJ, Barnard CF, Kelland LR, Harrap KR. Int J Cancer; 1994 Oct 01; 59(1):65-70. PubMed ID: 7927906 [Abstract] [Full Text] [Related]
36. Quantitative ultrastructural effects of cisplatin (Platinol), carboplatin (JM8), and iproplatin (JM9) on neurons of freshwater snail Lymnaea stagnalis. Müller LJ, Moorer-van Delft CM, Roubos EW, Vermorken JB, Boer HH. Cancer Res; 1992 Feb 15; 52(4):963-73. PubMed ID: 1737358 [Abstract] [Full Text] [Related]
37. Kinetic study on the reactions of platinum drugs with glutathione. Hagrman D, Goodisman J, Souid AK. J Pharmacol Exp Ther; 2004 Feb 15; 308(2):658-66. PubMed ID: 14610218 [Abstract] [Full Text] [Related]
38. [Pharmacological approach to the platinum compounds]. Sasaki Y. Gan To Kagaku Ryoho; 1992 Apr 15; 19(4):456-62. PubMed ID: 1313667 [Abstract] [Full Text] [Related]
39. Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin. Hecquet B, Caty A, Fournier C, Lefebvre JL, Adenis L. Bull Cancer; 1987 Apr 15; 74(4):433-6. PubMed ID: 3311237 [Abstract] [Full Text] [Related]
40. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. Kelland LR, Sharp SY, O'Neill CF, Raynaud FI, Beale PJ, Judson IR. J Inorg Biochem; 1999 Oct 15; 77(1-2):111-5. PubMed ID: 10626362 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]